Biotech · Private company · San Francisco, CA, US
Glycyx MOR Inc.
Track this companyFree. Adds Glycyx MOR Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials2
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaPHASE1_PHASE2 · RECRUITING · started Nov 30, 2026ClinicalTrials.gov NCT07631325 · fetched Nov 12, 2026
- Axelopran for Advanced Cancer in Patients Receiving OpioidsPHASE2 · RECRUITING · started Apr 27, 2026ClinicalTrials.gov NCT07354919 · fetched Nov 12, 2026
NIH awards2
- A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)Fiscal year 2026 · $1MNIH RePORTER 5R44CA306565-02 · fetched Nov 12, 2026
- A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)Fiscal year 2025 · $1.2MNIH RePORTER 1R44CA306565-01 · fetched Nov 12, 2026